Parkman Healthcare Partners LLC Grows Stake in LivaNova PLC (NASDAQ:LIVN)

Parkman Healthcare Partners LLC boosted its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 19.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 101,729 shares of the company's stock after purchasing an additional 16,570 shares during the quarter. Parkman Healthcare Partners LLC owned about 0.19% of LivaNova worth $5,345,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Driehaus Capital Management LLC boosted its holdings in shares of LivaNova by 64.7% in the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company's stock valued at $29,824,000 after buying an additional 213,749 shares in the last quarter. Perceptive Advisors LLC boosted its stake in LivaNova by 48.5% in the second quarter. Perceptive Advisors LLC now owns 444,000 shares of the company's stock valued at $24,340,000 after acquiring an additional 145,000 shares in the last quarter. Great Lakes Advisors LLC acquired a new position in LivaNova in the second quarter valued at $16,614,000. Price T Rowe Associates Inc. MD boosted its position in shares of LivaNova by 6.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,021 shares of the company's stock valued at $1,736,000 after purchasing an additional 1,980 shares during the period. Finally, Cornercap Investment Counsel Inc. acquired a new stake in shares of LivaNova in the 2nd quarter valued at about $1,103,000. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Trading Down 0.8 %

LivaNova stock traded down $0.43 during trading on Wednesday, reaching $51.19. The company had a trading volume of 492,082 shares, compared to its average volume of 608,748. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The firm has a market capitalization of $2.78 billion, a price-to-earnings ratio of 122.90 and a beta of 0.98. LivaNova PLC has a 12-month low of $42.75 and a 12-month high of $64.47. The stock's 50 day moving average price is $52.29 and its two-hundred day moving average price is $51.95.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Needham & Company LLC reissued a "buy" rating and issued a $75.00 price objective on shares of LivaNova in a report on Monday, November 25th. Mizuho decreased their price target on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, October 31st. Baird R W upgraded shares of LivaNova from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 17th. The Goldman Sachs Group began coverage on LivaNova in a research report on Friday, October 4th. They set a "buy" rating and a $65.00 price objective for the company. Finally, StockNews.com cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Saturday, November 16th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $69.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.